BETH ISRAEL DEACONESS MEDICAL CENTER
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1896-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.bidmc.org/
Self Hypnotic Relaxation As An Adjunct To Local Anesthesia During Large Core Breast Biopsy
- Conditions
- Interventions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 240
- Registration Number
- NCT00122369
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Tea's Effect on Atherosclerosis Pilot Study (TEA Study)
- Conditions
- First Posted Date
- 2005-07-15
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00120107
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Atrial Fibrillation Rate Control Therapy Guided By Continuous Ambulatory Monitoring
- Conditions
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Registration Number
- NCT00115843
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Tai Chi Mind-Body Therapy for Chronic Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2005-05-05
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT00110227
- Locations
- ๐บ๐ธ
Lown Cardiovascular Center, Brookline, Massachusetts, United States
๐บ๐ธBrigham and Women's Hospital, Boston, Massachusetts, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT00110149
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธNorris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
๐บ๐ธVermont Cancer Center at University of Vermont, Burlington, Vermont, United States
Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma
- Conditions
- First Posted Date
- 2004-09-02
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT00002781
- Locations
- ๐บ๐ธ
Boston University School of Medicine, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
- Conditions
- First Posted Date
- 2004-04-12
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Registration Number
- NCT00004082
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell Transplantation
- Conditions
- First Posted Date
- 2004-03-31
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 35
- Registration Number
- NCT00003412
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Registration Number
- NCT00006123
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธHackensack University Medical Center, Hackensack, New Jersey, United States
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT00073957
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธFletcher Allen Health Care - Medical Center Campus, Burlington, Vermont, United States